AMR(항생제 내성) 진단 시장 : 전략적 인사이트 및 예측(2026-2035년)

The AMR Diagnostics Market is anticipated to grow at a CAGR of 10.3% from USD 6.43 billion in 2026 to USD 15.59 billion in 2035.

The AMR diagnostics market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance and the global imperative for rapid, accurate diagnostic information to guide targeted therapy. The market's evolution is characterized by a paradigm shift from conventional culture-based methods toward molecular diagnostics, next-generation sequencing, and integrated susceptibility testing platforms. Healthcare systems are increasingly demanding diagnostic information much earlier in the treatment pathway because inappropriate antibiotic selection contributes to poorer clinical outcomes and accelerates resistance development. Rapid diagnostics are therefore becoming an integral component of antimicrobial stewardship rather than solely laboratory testing tools. The convergence of molecular diagnostics, automation, and artificial intelligence is enabling faster pathogen identification and resistance detection. Healthcare infrastructure modernization is increasing diagnostic adoption through automated platforms capable of integrating organism identification with susceptibility testing and digital reporting. Regulatory organizations continue to recognize diagnostics as a critical component of AMR mitigation strategies, encouraging manufacturers to maintain clinical relevance despite evolving microbial resistance patterns. The market is witnessing significant investment in rapid phenotypic testing, genomic surveillance platforms, and AI-enabled interpretation tools, positioning AMR diagnostics as a cornerstone of modern infectious disease management and public health preparedness.

Market Drivers

• The growing burden of antimicrobial resistance represents the primary driver for the AMR diagnostics market. AMR is creating a significant clinical burden because resistant pathogens reduce the effectiveness of standard antimicrobial therapies. Healthcare providers are increasingly requiring rapid diagnostic information as empirical treatment becomes less reliable for severe infections. Delayed pathogen identification limits therapeutic precision and increases the probability of inappropriate antibiotic utilization. Diagnostic manufacturers are expanding platforms that combine organism identification with resistance detection to support faster treatment decisions. This shift strengthens demand for advanced AMR diagnostics across hospital and public health settings, resulting in sustained growth in AMR diagnostic utilization. The expansion of antimicrobial stewardship programs is further accelerating market growth through increased demand for rapid diagnostics. Antimicrobial stewardship programs have become a core component of healthcare quality initiatives because healthcare systems seek to reduce unnecessary antibiotic exposure. Hospitals are increasingly monitoring antimicrobial prescribing patterns as resistance rates continue to rise across multiple pathogen categories. Conventional diagnostic workflows often delay treatment optimization, creating pressure for faster and more actionable laboratory results. Healthcare institutions are adopting rapid diagnostic technologies that enable earlier antimicrobial intervention and therapy adjustment. This transition increases the strategic value of AMR diagnostics within routine clinical workflows. The increasing adoption of molecular diagnostics is driving demand for faster pathogen detection. Molecular diagnostic technologies provide faster pathogen detection than traditional culture-based approaches. Clinical laboratories are integrating PCR-based and multiplex testing platforms because clinicians require timely information for critical infections. Conventional culture remains important for susceptibility determination, yet turnaround time limitations create operational constraints in acute care environments. Manufacturers are developing highly automated molecular systems that simplify laboratory implementation while maintaining analytical performance. Strengthening surveillance and public health initiatives is supporting market expansion through infrastructure investment. Governments and international organizations recognize AMR as a major public health threat. National surveillance programs are expanding data collection efforts to improve understanding of resistance patterns across healthcare systems.

Market Restraints

• High capital investment requirements limit adoption of advanced molecular diagnostic platforms among smaller healthcare facilities and resource-constrained laboratories. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Limited reimbursement coverage for certain rapid diagnostic technologies reduces purchasing incentives despite demonstrated clinical benefits. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Shortages of skilled microbiologists, molecular diagnosticians, and bioinformatics specialists constrain implementation of complex diagnostic workflows. The shortage of specialized personnel limits the scalability of advanced AMR diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of integrated diagnostic ecosystems and automation. Culture-based susceptibility testing remains the clinical reference standard because it directly evaluates antimicrobial effectiveness against isolated pathogens. Demand is increasingly shifting toward PCR, NGS, MALDI-TOF, microarray, and isothermal amplification technologies because clinicians require faster diagnostic information. Conventional culture methods often create treatment delays that prolong empirical antibiotic use and increase healthcare costs. Molecular and sequencing technologies are reducing turnaround times while expanding the ability to identify resistance genes and emerging resistance mechanisms. The segment analysis reveals that bacterial pathogens represent the largest focus area because bacterial AMR continues driving significant healthcare burdens worldwide. Healthcare systems are increasingly monitoring fungal resistance as invasive fungal infections become more common among immunocompromised patient populations. Resistance mechanisms including beta-lactam resistance, carbapenem resistance, methicillin resistance, vancomycin resistance, and multidrug resistance represent critical testing targets. Blood, urine, and respiratory samples constitute major specimen types for AMR testing. Hospitals represent the leading end-user segment, with clinical diagnostic laboratories and public health laboratories expanding testing capacity. The integration of AI is becoming increasingly important because diagnostic datasets are becoming more complex as laboratories integrate molecular testing, sequencing, and advanced susceptibility platforms. Technology providers are incorporating AI and machine learning capabilities that support automated result interpretation and clinical decision support.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized molecular and sequencing providers. Thermo Fisher Scientific occupies a strategically important position because it combines molecular diagnostics, sequencing technologies, laboratory instruments, reagents, and bioinformatics capabilities within a single ecosystem, expanding genomic and molecular diagnostic capabilities that simplify laboratory operations while supporting high-throughput testing requirements. Roche maintains a strong competitive position because of its extensive expertise in molecular diagnostics, infectious disease testing, and healthcare data integration, expanding molecular diagnostic solutions that provide clinically actionable information while supporting laboratory efficiency. bioMerieux is strategically distinct because of its longstanding focus on clinical microbiology, infectious disease diagnostics, and antimicrobial susceptibility testing, enhancing automated microbiology solutions that improve laboratory efficiency while delivering actionable susceptibility information. BD occupies an important position because it combines microbiology expertise, automated laboratory systems, and infectious disease diagnostics, expanding automation capabilities that improve laboratory productivity while supporting diagnostic accuracy. Danaher, through Cepheid and Beckman Coulter, provides molecular diagnostics, microbiology solutions, automation technologies, and laboratory workflow management capabilities, expanding molecular testing capabilities that support rapid pathogen identification and resistance detection. QIAGEN differentiates itself through its strong focus on molecular diagnostics, sample preparation technologies, and bioinformatics solutions that support infectious disease testing and resistance monitoring, expanding syndromic testing and molecular detection capabilities. Companies are pursuing product portfolio expansion through innovation in rapid phenotypic testing, NGS platforms, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and public health organizations are increasing, driven by the need for surveillance and stewardship. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

• The AMR diagnostics market is positioned for sustained growth driven by the convergence of antimicrobial resistance burden, stewardship programs, and technological innovation. The transition from conventional culture-based methods toward integrated molecular and genomic platforms represents a fundamental shift in infectious disease diagnostics. While challenges related to high costs, reimbursement variability, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with AMR diagnostics evolving into a cornerstone of modern infectious disease management, supporting rapid pathogen identification, resistance detection, and public health surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. AMR Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Antimicrobial Resistance (AMR): Disease and Public Health Overview
• 3.3 Evolution of AMR Diagnostic Technologies
• 3.4 Key Market Trends
• 3.5 Global AMR Burden Analysis
• 3.6 Prevalence of Drug-Resistant Pathogens
• 3.7 Diagnosed Patient Population Analysis
• 3.8 Testing Volume Analysis
• 3.9 Current Diagnostic and Clinical Management Landscape
• 3.10 Historical Market Size Analysis (2021-2025)
• 3.11 Market Forecast Analysis (2026-2035)

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in AMR Diagnostics
• 6.2 Product Innovation Trends
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Next-Generation Sequencing (NGS) Integration
• 6.6 AI and Bioinformatics Integration
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. AMR Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by End User Environment

9. AMR Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product Type
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Analytics Solutions
• 9.2 By Technology
  • 9.2.1 Culture-Based Susceptibility Testing
  • 9.2.2 Polymerase Chain Reaction (PCR)
  • 9.2.3 Next-Generation Sequencing (NGS)
  • 9.2.4 Microarray-Based Diagnostics
  • 9.2.5 Mass Spectrometry (MALDI-TOF)
  • 9.2.6 Isothermal Amplification Technologies
  • 9.2.7 Other Molecular Diagnostic Technologies
• 9.3 By Pathogen Type
  • 9.3.1 Bacterial Pathogens
  • 9.3.2 Fungal Pathogens
  • 9.3.3 Viral Pathogens
• 9.4 By Resistance Mechanism
  • 9.4.1 ?-Lactam Resistance
  • 9.4.2 Carbapenem Resistance
  • 9.4.3 Methicillin Resistance
  • 9.4.4 Vancomycin Resistance
  • 9.4.5 Multidrug Resistance
• 9.5 By Sample Type
  • 9.5.1 Blood
  • 9.5.2 Urine
  • 9.5.3 Respiratory Samples
  • 9.5.4 Wound Samples
  • 9.5.5 Stool Samples
  • 9.5.6 Other Sample Types
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Clinical Diagnostic Laboratories
  • 9.6.3 Academic & Research Institutes
  • 9.6.4 Public Health Laboratories
  • 9.6.5 Other End Users

10. AMR Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. AMR Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Thermo Fisher Scientific Inc.
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 bioMerieux SA
• 13.4 Becton, Dickinson and Company
• 13.5 Danaher Corporation (Cepheid, Beckman Coulter)
• 13.6 QIAGEN N.V.
• 13.7 Bruker Corporation
• 13.8 Abbott Laboratories
• 13.9 Sysmex Corporation
• 13.10 Accelerate Diagnostics, Inc.
• 13.11 T2 Biosystems, Inc.
• 13.12 OpGen, Inc.
• 13.13 Revvity, Inc.
• 13.14 Oxford Nanopore Technologies plc
• 13.15 Seegene Inc.

14. AMR Diagnostics Market Commercial Forecast Analysis

• 14.1 Culture-Based Susceptibility Testing Diagnostics Forecast
• 14.2 PCR-Based AMR Diagnostics Forecast
• 14.3 NGS-Based AMR Diagnostics Forecast
• 14.4 MALDI-TOF-Based AMR Diagnostics Forecast
• 14.5 Rapid Syndromic Testing Solutions Forecast
• 14.6 Reagents & Consumables Forecast
• 14.7 Software & Bioinformatics Solutions Forecast

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends